JP2008520694A - 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法 - Google Patents
非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法 Download PDFInfo
- Publication number
- JP2008520694A JP2008520694A JP2007543244A JP2007543244A JP2008520694A JP 2008520694 A JP2008520694 A JP 2008520694A JP 2007543244 A JP2007543244 A JP 2007543244A JP 2007543244 A JP2007543244 A JP 2007543244A JP 2008520694 A JP2008520694 A JP 2008520694A
- Authority
- JP
- Japan
- Prior art keywords
- healing
- curcumin
- arginine
- nitroglycerin
- ulcers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 68
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 42
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 41
- 230000035876 healing Effects 0.000 title abstract description 44
- 230000003111 delayed effect Effects 0.000 title abstract description 16
- 238000000034 method Methods 0.000 title description 14
- 230000001737 promoting effect Effects 0.000 title description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 112
- 235000012754 curcumin Nutrition 0.000 claims abstract description 56
- 229940109262 curcumin Drugs 0.000 claims abstract description 56
- 239000004148 curcumin Substances 0.000 claims abstract description 56
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 56
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000004475 Arginine Substances 0.000 claims abstract description 33
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 31
- 239000000006 Nitroglycerin Substances 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 30
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 12
- 229960003121 arginine Drugs 0.000 claims abstract description 9
- 239000006071 cream Substances 0.000 claims abstract description 9
- 239000003974 emollient agent Substances 0.000 claims abstract description 9
- 239000002480 mineral oil Substances 0.000 claims abstract description 5
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229940072991 nitro-bid Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims 2
- 239000003860 topical agent Substances 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011787 zinc oxide Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 68
- 235000009697 arginine Nutrition 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 230000029663 wound healing Effects 0.000 description 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 229930064664 L-arginine Natural products 0.000 description 10
- 235000014852 L-arginine Nutrition 0.000 description 10
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 10
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 230000004087 circulation Effects 0.000 description 8
- 238000001804 debridement Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000003790 Foot Ulcer Diseases 0.000 description 5
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011542 limb amputation Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- PGHBYDVOOPRPQW-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O PGHBYDVOOPRPQW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MXCVHSXCXPHOLP-UHFFFAOYSA-N 4-oxo-6-propylchromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=CC(CCC)=CC=C21 MXCVHSXCXPHOLP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- GVYBVPCYMLCVKB-INZIHYEWSA-N COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] Chemical compound COC1=CC(=CC=C1O)C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1.N[C@@H](CCCNC(N)=N)C(=O)O.C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] GVYBVPCYMLCVKB-INZIHYEWSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 101000800556 Methanobrevibacter olleyae NAD(+) hydrolase TcpO Proteins 0.000 description 1
- 241001363490 Monilia Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 231100000674 Phytotoxicity Toxicity 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- GEVPIWPYWJZSPR-UHFFFAOYSA-N tcpo Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)C(=O)OC1=C(Cl)C=C(Cl)C=C1Cl GEVPIWPYWJZSPR-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/992,623 US7731993B2 (en) | 2004-11-17 | 2004-11-17 | Composition for treating a dermal anomaly |
| US10/992,636 US20060105027A1 (en) | 2004-11-17 | 2004-11-17 | Method for treating skin ulcers |
| PCT/US2005/041708 WO2006055726A2 (fr) | 2004-11-17 | 2005-11-17 | Composition et methode destinees a ameliorer la cicatrisation de plaies et d'ulcerations qui ne cicatrisent pas ou qui cicatrisent lentement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008520694A true JP2008520694A (ja) | 2008-06-19 |
Family
ID=36407755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543244A Pending JP2008520694A (ja) | 2004-11-17 | 2005-11-17 | 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1827466A4 (fr) |
| JP (1) | JP2008520694A (fr) |
| AU (1) | AU2005307736A1 (fr) |
| BR (1) | BRPI0517731A (fr) |
| CA (1) | CA2588119A1 (fr) |
| IL (1) | IL183117A0 (fr) |
| WO (1) | WO2006055726A2 (fr) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61286327A (ja) * | 1985-06-12 | 1986-12-16 | Sanwa Kagaku Kenkyusho:Kk | 移植皮膚処置剤 |
| JPH10507443A (ja) * | 1994-10-05 | 1998-07-21 | カエセマイアー，ダブリュー，エイチ | 一酸化窒素の合成を刺激する方法及び製剤 |
| JPH10251133A (ja) * | 1997-03-06 | 1998-09-22 | Noevir Co Ltd | 皮膚外用剤 |
| JPH11501629A (ja) * | 1995-03-06 | 1999-02-09 | インターナショナル メディカル イノベーションズ インク． | ニトログリセリン含有の水性局所用クリーム；その製造方法及び使用 |
| WO1999042094A1 (fr) * | 1995-08-24 | 1999-08-26 | Heng Madalene C Y | Utilisation de la curcumine pour traiter le psoriasis, les plaies cutanees, les brulures et l'eczema |
| JP2002504523A (ja) * | 1998-02-27 | 2002-02-12 | シンクロニュ−ロン，エルエルシ− | 肛門部の痛みのある状態を治療するための方法及びそのための組成物 |
| US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196185A (en) * | 1989-09-11 | 1993-03-23 | Micro-Collagen Pharmaceutics, Ltd. | Collagen-based wound dressing and method for applying same |
| US5401504B1 (en) * | 1993-12-28 | 1998-04-21 | Univ Mississippi Medical Cente | Use of tumeric in wound healing |
| ES2292402T3 (es) * | 1994-05-27 | 2008-03-16 | Strakan International Limited | Composicion de donador de oxido nitrico y metodo para el tratamiento de afecciones anales. |
| US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
| US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| US20030104033A1 (en) * | 2001-07-13 | 2003-06-05 | Lai Chon-Si | Enteral formulations |
-
2005
- 2005-11-17 AU AU2005307736A patent/AU2005307736A1/en not_active Abandoned
- 2005-11-17 WO PCT/US2005/041708 patent/WO2006055726A2/fr active Application Filing
- 2005-11-17 EP EP05826664A patent/EP1827466A4/fr not_active Withdrawn
- 2005-11-17 BR BRPI0517731-6A patent/BRPI0517731A/pt not_active IP Right Cessation
- 2005-11-17 CA CA002588119A patent/CA2588119A1/fr not_active Abandoned
- 2005-11-17 JP JP2007543244A patent/JP2008520694A/ja active Pending
-
2007
- 2007-05-10 IL IL183117A patent/IL183117A0/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61286327A (ja) * | 1985-06-12 | 1986-12-16 | Sanwa Kagaku Kenkyusho:Kk | 移植皮膚処置剤 |
| JPH10507443A (ja) * | 1994-10-05 | 1998-07-21 | カエセマイアー，ダブリュー，エイチ | 一酸化窒素の合成を刺激する方法及び製剤 |
| JPH11501629A (ja) * | 1995-03-06 | 1999-02-09 | インターナショナル メディカル イノベーションズ インク． | ニトログリセリン含有の水性局所用クリーム；その製造方法及び使用 |
| WO1999042094A1 (fr) * | 1995-08-24 | 1999-08-26 | Heng Madalene C Y | Utilisation de la curcumine pour traiter le psoriasis, les plaies cutanees, les brulures et l'eczema |
| JPH10251133A (ja) * | 1997-03-06 | 1998-09-22 | Noevir Co Ltd | 皮膚外用剤 |
| JP2002504523A (ja) * | 1998-02-27 | 2002-02-12 | シンクロニュ−ロン，エルエルシ− | 肛門部の痛みのある状態を治療するための方法及びそのための組成物 |
| US20030091601A1 (en) * | 2001-11-13 | 2003-05-15 | Abat Inc. | Use of topical arginine to enhance wound healing |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0517731A (pt) | 2008-10-21 |
| IL183117A0 (en) | 2007-10-31 |
| WO2006055726A3 (fr) | 2007-03-22 |
| CA2588119A1 (fr) | 2006-05-26 |
| EP1827466A2 (fr) | 2007-09-05 |
| EP1827466A4 (fr) | 2009-11-11 |
| AU2005307736A1 (en) | 2006-05-26 |
| WO2006055726A2 (fr) | 2006-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6495183B2 (ja) | 表面の創傷を処置するための組成物および方法 | |
| JP2012107014A (ja) | イオン性銀錯体 | |
| JP2021105046A (ja) | 高張性抗微生物治療用組成物 | |
| AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| BR112012001491B1 (pt) | Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica | |
| US20090036413A1 (en) | Compositions, uses, and method of making wound care products from naturally occurring food ingredients | |
| US20140271864A1 (en) | Therapeutic compositions for bone repair | |
| JP2009523704A (ja) | 創傷バイオフィルムを破壊する、および創傷バイオフィルム再構成を阻害するための組成物 | |
| SK287249B6 (sk) | Liečivé produkty s cikatrizačným účinkom obsahujúce biguanidové deriváty | |
| US8492435B2 (en) | Composition for treating a dermal anomaly | |
| CN102365075A (zh) | 医用抗菌乳膏和其制备方法 | |
| WO2008104076A1 (fr) | Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée | |
| US11109607B2 (en) | Oil-based compositions for enhancing oral health and general wellness in humans | |
| JP2010100596A (ja) | マスティックとスクワランを配合した薬剤耐性菌感染予防の組成物 | |
| KR20140104823A (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| JP2008520694A (ja) | 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法 | |
| US20080045604A1 (en) | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations | |
| KR101548254B1 (ko) | 유황, 명반 및 식초를 유효성분으로 포함하는 피부 질환 치료용 조성물 | |
| CN115364097B (zh) | 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用 | |
| Rajashri et al. | Curcuma Longa and Pineapple Extract Paste in the management of Alveolar Osteitis: An Experimental study | |
| US20230190792A1 (en) | Topical preparations | |
| WO2015159206A1 (fr) | Microparticules d'alliage de cuivre destinées à être utilisées dans le traitement d'une lésion cutanée externe | |
| El-Seddawy et al. | Dexpanthenol: New Insights on Wound Healing, a Review | |
| US20100189668A1 (en) | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition | |
| US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081020 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120217 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120316 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120417 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120424 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130415 |